Stock Scorecard



Stock Summary for Outlook Therapeutics Inc (OTLK) - $1.04 as of 9/12/2025 9:16:37 PM EST

Total Score

5 out of 30

Safety Score

27 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for OTLK

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for OTLK

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for OTLK

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for OTLK

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for OTLK (27 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for OTLK

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight ( EIS ) 9/3/2025 12:35:00 PM
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight ( EIS ) 9/3/2025 12:35:00 PM
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight ( EIS ) - Outlook Therapeutics ( NASDAQ:OTLK ) 9/3/2025 12:35:00 PM
Outlook Therapeutics Requests Type A Meeting with FDA 9/2/2025 12:35:00 PM
Outlook Therapeutics Requests Type A Meeting with FDA 9/2/2025 12:35:00 PM
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug 8/29/2025 2:38:00 PM
Nasdaq Surges 100 Points; Dollar General Earnings Beat Views - CaliberCos ( NASDAQ:CWD ) , Accelerant Holdings ( NYSE:ARX ) 8/28/2025 4:54:00 PM
Gene and Oral Therapies Drive Urgency and Innovation in Retinal Care, Reshaping Ophthalmology's Future, According to Spherix Global Insights 8/28/2025 4:12:00 PM
FDA Rejects Outlook Therapeutics Eye Drug For Second Time - Outlook Therapeutics ( NASDAQ:OTLK ) 8/28/2025 3:15:00 PM
US Stocks Mixed; Nvidia Posts Upbeat Earnings - CaliberCos ( NASDAQ:CWD ) , AquaBounty Techs ( NASDAQ:AQB ) 8/28/2025 2:27:00 PM

Financial Details for OTLK

Company Overview

Ticker OTLK
Company Name Outlook Therapeutics Inc
Country USA
Description Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 1.04
Price 4 Years Ago 27.20
Last Day Price Updated 9/12/2025 9:16:37 PM EST
Last Day Volume 5,511,006
Average Daily Volume 5,763,172
52-Week High 6.98
52-Week Low 0.79
Last Price to 52 Week Low 31.65%

Valuation Measures

Trailing PE N/A
Industry PE 21.34
Sector PE 40.86
5-Year Average PE -43.38
Free Cash Flow Ratio 5.20
Industry Free Cash Flow Ratio 13.20
Sector Free Cash Flow Ratio 29.37
Current Ratio Most Recent Quarter 0.67
Total Cash Per Share 0.20
Book Value Per Share Most Recent Quarter -0.86
Price to Book Ratio 10.19
Industry Price to Book Ratio 28.96
Sector Price to Book Ratio 32.27
Price to Sales Ratio Twelve Trailing Months 29.51
Industry Price to Sales Ratio Twelve Trailing Months 44.01
Sector Price to Sales Ratio Twelve Trailing Months 19.72
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 44,419,500
Market Capitalization 46,196,280
Institutional Ownership 20.54%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -27.78%
Reported EPS 12 Trailing Months -0.84
Reported EPS Past Year -1.78
Reported EPS Prior Year -3.36
Net Income Twelve Trailing Months -43,440,502
Net Income Past Year -75,367,000
Net Income Prior Year -58,983,000
Quarterly Revenue Growth YOY 658.00%
5-Year Revenue Growth -53.87%
Operating Margin Twelve Trailing Months -1,046.00%

Balance Sheet

Total Cash Most Recent Quarter 8,900,814
Total Cash Past Year 14,927,538
Total Cash Prior Year 23,391,982
Net Cash Position Most Recent Quarter -11,536,186
Net Cash Position Past Year -14,512,462
Long Term Debt Past Year 29,440,000
Long Term Debt Prior Year 71,102,000
Total Debt Most Recent Quarter 20,437,000
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year -73,076,510
Total Stockholder Equity Prior Year -14,437,777
Total Stockholder Equity Most Recent Quarter -37,189,725

Free Cash Flow

Free Cash Flow Twelve Trailing Months -56,434,146
Free Cash Flow Per Share Twelve Trailing Months -1.27
Free Cash Flow Past Year -68,793,858
Free Cash Flow Prior Year -42,973,400

Options

Put/Call Ratio 0.01
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.34
MACD Signal -0.24
20-Day Bollinger Lower Band 0.89
20-Day Bollinger Middle Band 1.76
20-Day Bollinger Upper Band 2.62
Beta 0.49
RSI 40.60
50-Day SMA 2.44
150-Day SMA 11.16
200-Day SMA 15.29

System

Modified 9/11/2025 6:57:19 AM EST